Alzinova AB (publ) (ALZ.ST)
- Previous Close
1.2400 - Open
1.2400 - Bid 1.2000 x --
- Ask 1.2300 x --
- Day's Range
1.1800 - 1.2500 - 52 Week Range
0.9493 - 3.9150 - Volume
284,071 - Avg. Volume
184,295 - Market Cap (intraday)
67.625M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.26
Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer's disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in Mölndal, Sweden.
www.alzinova.comRecent News: ALZ.ST
Performance Overview: ALZ.ST
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALZ.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALZ.ST
Valuation Measures
Market Cap
68.18M
Enterprise Value
46.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
227.25
Price/Book (mrq)
0.63
Enterprise Value/Revenue
156.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-95.10%
Return on Assets (ttm)
-9.60%
Return on Equity (ttm)
-16.34%
Revenue (ttm)
18.05M
Net Income Avi to Common (ttm)
-17.17M
Diluted EPS (ttm)
-0.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
13.01M
Total Debt/Equity (mrq)
0.74%
Levered Free Cash Flow (ttm)
-28.13M